<DOC>
	<DOCNO>NCT01818167</DOCNO>
	<brief_summary>The purpose study compare efficacy Provodine™ topical cream 10 % benzoyl peroxide topical body wash treatment early stage hidradenitis suppurativa .</brief_summary>
	<brief_title>An Investigation Into Efficacy Provodine Topical Cream Compared 10 % Benzoyl Peroxide Wash Treatment Hidradenitis Suppurativa .</brief_title>
	<detailed_description>Hidradenitis suppurativa ( HS ) chronic , recurrent inflammatory disease skin . It typically manifest nodule abscesses ultimately progress form deep sinus tract , fistula , scar . It affect area body apocrine gland bearing tissue , include anogenital , axillary inframammary region . The lesion often painful chronically drain malodorous fluid , leave affect individual uncomfortable self-conscious , even debilitate . The pathogenesis disease process fully understood , HS difficult treat . Measures topical antibiotic antiseptic wash generally think beneficial treatment early stage HS . Although controlled trial treatment HS , commonly use topical wash currently include benzoyl peroxide chlorhexidine gluconate . Provodine™ topical cream design actively kill microbe skin 6 hour without result irritation often associate repetitive use antimicrobial product . A blinded control comparison Provodine™ versus current standard benzoyl peroxide wash allow alternative treatment early stage HS also provide additional tool arsenal treatment disease process .</detailed_description>
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>For inclusion , subject must : 1 . Be least 13 year old . 2 . Be otherwise healthy . 3 . Have diagnosis HS . 4 . Patients must Hurley stage I Stage II HS 5 . Be able understand requirement study , risk involve , able sign inform consent form . 6 . Agree follow undergo studyrelated procedure . 7 . If applicable , minor must permission legal guardian participation study . Subjects meet follow criterion exclude : 1 . Patients HS Hurley stage III exclude participation study 2 . Patients pregnant breast feed able take part study due unknown effect topical medication . 3 . Concomitant use systemic topical treatment HS involve current study . For cohort I , washout period systemic and/or topical medication require . For Cohort II , 14 day minimum washout period systemic topical treatment HS . 4 . Any reason investigator feel patient participate study . 5 . If patient miss ≥ 2 consecutive study visit , patient exclude participation trial . 6 . History allergy iodine benzoyl peroxide .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Hidradenitis Suppurativa</keyword>
	<keyword>HS</keyword>
	<keyword>Acne Inversa</keyword>
	<keyword>Velpeau 's disease</keyword>
	<keyword>Verneuil 's disease</keyword>
</DOC>